FindTrial
Sign In

the prognostic role of morphine-3 glucuronide level in patients with non-small-cell lung cancer receiving long period morphine therapy

the prognostic role of morphine-3 glucuronide level in patients with non-small-cell lung cancer receiving long period morphine therapy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OOC-17013001
Enrollment
Unknown
Registered
2017-10-16
Start date
2017-10-16
Completion date
Unknown
Last updated
2017-10-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non small cell lung cancer

Interventions

Case series:morphine therapy

Sponsors

Tianjin Medical University Cancer Institute and Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: patients diagnosed as non small cell lung cancer with TNM stage IIIB-IV receiving morphine therapy and under the treatment complied with NCCN guidelines.

Exclusion criteria

Exclusion criteria: 1. allergic to morphine; 2. history of asthma; 3. serious cardiac, pulmonary, liver or kidney dysfunction; 4. communication disorders or history of mental disease; 5. BMI32; 6. incomplete follow-up data.

Design outcomes

Primary

MeasureTime frame
M3G;—

Secondary

MeasureTime frame
plasma concentration of morphine;plasma concentration of M6G;—

Countries

China

Contacts

Public ContactWang Kaiyuan

Tianjin Medical University Cancer Institute and Hospital

93445729@qq.com+86 022-23340123

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026